Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma

Journal of Clinical Oncology

Volumn 31, Issue 6, 2013, Pages 744-751

  Zhong, Lai Ping ^a   Zhang, Chen Ping ^a   Ren, Guo Xin ^a   Guo, Wei ^a   William, William N ^a   Sun, Jian ^a   Zhu, Han Guang ^a   Tu, Wen Yong ^a   Li, Jiang ^a   Cai, Yi Li ^a   Wang, Li Zhen ^a   Fan, Xin Dong ^a   Wang, Zhong He ^a   Hu, Yong Jie ^a   Ji, Tong ^a   Yang, Wen Jun ^a   Ye, Wei Min ^a   Li, Jun ^a   He, Yue ^a   Wang, Yan An ^a   Xu, Li Qun ^a   Wang, Bo Song ^a   Kies, Merrill S ^a   Lee, J Jack ^a   Myers, Jeffrey N ^a   Zhang, Zhi Yuan ^a   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84875715657     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.8820     Document Type: Article

References (28)

1. Kademani D: Oral cancer. Mayo Clin Proc 82:878-887, 2007 (Pubitemid 47015470)
2. Petersen PE: The World Oral Health Report 2003: Continuous improvement of oral health in the 21st century - The approach of WHO Global Oral Programme. Community Dent Oral Epidemiol 31:3-23, 2003 (suppl 1)
3. Neville BW, Day TA: Oral cancer and precancerous lesions. CA Cancer J Clin 52:195-215, 2002
4. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005 (Pubitemid 40372904)
5. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers (version 1.2012). http://www.nccn.org/ professionals/physician-gls/pdf/headand- neck.pdf
6. Division of Oral and Maxillofacial Oncology, Chinese Society of Oral and Maxillofacial Surgery: The protocol of treatment guideline of oral and maxillofacial malignant neoplasms. China J Oral Maxillofac Surg 8:98-106, 2010
7. Licitra L, Grandi C, Guzzo M, et al: Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. J Clin Oncol 21:327-333, 2003 (Pubitemid 46606163)
8. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data - MACH-NC Collaborative Group: Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949- 955, 2000 (Pubitemid 30148259)
9. Pignon JP, le Maître A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
10. Brockstein B, Haraf DJ, Rademaker AW: Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol 15:1179-1186, 2004 (Pubitemid 39199304)
11. Posner RM, Hershock MD, Blajman RC, et al: Cisplatin and fluorouracil alone or with docetaxel inhead and neck cancer. N Engl J Med 357:1705- 1715, 2007
12. Vermorken BJ, Remenar E, Herpen VC, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695- 1704, 2007 (Pubitemid 350005151)
13. Lorch JH, Goloubeva O, Haddad RI, et al: Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153-159, 2011
14. Cohen EE, Karrison T, Kocherginsky M, et al: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30:356s, 2012 (suppl 15; abstr 5500)
15. Haddad RI, Rabinowits G, Tishler RB, et al: The RARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC). J Clin Oncol 30:356s, 2012 (suppl 15; abstr 5501)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Yang AK, Liu TR, Chen FJ, et al: Survival analysis of 229 patients with advanced squamous cell carcinoma of the oral tongue [in Chinese]. Ai Zheng 27:1315-1320, 2008
18. Guo ZM, Wang YL, Zhang Q, et al: Treatment and prognosis of gingival carcinoma: A report of 116 cases [in Chinese]. Ai Zheng 27:307-310, 2008
19. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organisation for Research and Treatment of Cancer phase III trial - EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890-899, 1996 (Pubitemid 26230640)
20. Terrell JE, Fisher SG, Wolf GT: Long-term quality of life after treatment of laryngeal cancer: The Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 124:964-971, 1998 (Pubitemid 28411497)
21. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
22. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004 (Pubitemid 38580197)
23. Kies MS, Boatright DH, Li G, et al: Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck 34:1255-1262, 2012
24. Temam S, Flahault A, Pé drié S, et al: p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregioally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18:385-394, 2000 (Pubitemid 30056429)
25. Perrone F, Bossi P, Cortelazzi B, et al: TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 28:761-766, 2010
26. Wu Y, Posner MR, Schumaker LM, et al: Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: An analysis of the TAX 324 trial. Cancer 118:1811-1817, 2012
27. Kumar B, Cordell KG, Lee JS, et al: EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128-3137, 2008
28. Cullen KJ, Schumaker L, Nikitakis N, et al: Beta-tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: A companion analysis of the TAX 324 trial. J Clin Oncol 27:6222-6228, 2009